Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IncyteMEX:INCY 85 EV-to-EBITDA is 9.29 as of Aug. 12, 2026, which is 49% below its 10-year median of 18.28. GuruFocus rates MEX:INCY with a GF Score™ of 85/100 and a GF Value™ of MXN1,773.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 398 Biotechnology companies, Incyte ranks better than 57.29% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Incyte's enterprise value is MXN343,525 Mil.
Incyte's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was MXN36,983 Mil. Therefore, Incyte's EV-to-EBITDA for today is 9.29.
The historical rank and industry rank for Incyte's EV-to-EBITDA or its related term are showing as below:
MEX:INCY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1494.86 Med: 18.28 Max: 141.66
Current: 9.69
During the past 13 years, the highest EV-to-EBITDA of Incyte was 141.66. The lowest was -1494.86. And the median was 18.28.
MEX:INCY's EV-to-EBITDA is ranked better than 57.29% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs MEX:INCY: 9.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-12), Incyte's stock price is MXN2036.00.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN140.331. Therefore, Incyte's PE Ratio (TTM) for today is 14.51.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Incyte's share price for today is MXN2036.00.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN140.331.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Incyte's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INCY vs INSM, BNTX, ROIV: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Incyte's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Incyte's EV-to-EBITDA falls into.
Incyte's current Enterprise Value is MXN343,525 Mil.
Incyte's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN36,983 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MEX:INCY) has a EV-to-EBITDA of 9.29 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Incyte. This is 49% below median its historical median of 18.28. According to the industry distribution chart, Incyte ranks #170 out of 398 companies in the Biotechnology industry, placing it in the top 42.7%.
Is Incyte's EV-to-EBITDA too high?
Incyte's current EV-to-EBITDA of 9.29 is 49% below median its 10-year median of 18.28. The Biotechnology industry median EV-to-EBITDA is 13.40. Incyte's value of 9.29 is 30.6% below this industry median. Based on the distribution chart, Incyte ranks #170 out of 398 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Incyte has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's EV-to-EBITDA compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #170 out of 398 companies for EV-to-EBITDA. This puts Incyte in the upper half of its industry. The industry median EV-to-EBITDA is 13.40. Incyte's value of 9.29 is 30.6% below this benchmark. While the company's 10-year median is 18.28 vs. the industry median of 13.40, Incyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current EV-to-EBITDA of 9.29 is 30.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Incyte. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current EV-to-EBITDA is 9.29, which is 49% below median its own 10-year median of 18.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,773.66, compared to a current price of MXN2,036.00 — trading 14.8% above its estimated fair value. The current EV-to-EBITDA is 9.29, which is 49% below median its 10-year median of 18.28 and 30.6% below the Biotechnology industry median of 13.40. Incyte's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Incyte (MEX:INCY), the current EV-to-EBITDA is 9.29 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN2,036.00 is trading 14.8% above its estimated GF Value™ of MXN1,773.66.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
EV-to-EBITDA: 9.29 (49% below median its 10-year median of 18.28)
GF Value™: MXN1,773.66 vs. price of MXN2,036.00 (14.8% above fair value)
Industry Position: 30.6% below the Biotechnology median (#170 of 398)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
85GF Score
Get the complete analysis for MEX:INCY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
